PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Dulaglutide

LY2189265; Trulicity

Classification: GLP-1 receptor agonist

Mechanism: GLP-1 receptor agonist fused to human IgG4 Fc

Benefits: T2D glycemic control; modest weight loss; cardiovascular protection (REWIND)

Evidence tier: FDA-Approved · Availability: Prescription

Primary sources

  1. FDA Trulicity (dulaglutide) prescribing information
  2. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) — placebo-controlled trial. Lancet 2019. PMID 31189511
  3. Dungan KM et al. Once-weekly dulaglutide added to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab 2016. PMID 26799540

Loading interactive view…